Form 4: Arcutis Biotherapeutics Director Howard G. Welgus Executes Stock Sale Under 10b5-1 Plan

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) common stock at an average price of $15.1236, executed under a pre-arranged 10b5-1 trading plan.

Summary

• On April 1, 2025, Howard G. Welgus, a director of Arcutis Biotherapeutics, sold 10,000 shares of common stock.
• The sale was executed under a 10b5-1 trading plan adopted on March 5, 2024, with an end date of May 30, 2025.
• The shares were sold at a weighted average price of $15.1236, with individual prices ranging from $14.83 to $15.57.
• Following the transaction, Welgus directly owns 121,944 shares of Arcutis Biotherapeutics.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each respective price within the stated range upon request.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Industry Context

Sales by company insiders are a normal part of corporate governance. The use of a 10b5-1 trading plan suggests the insider is selling shares in a pre-planned manner to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Howard G. Welgus, Form 4, Stock Sale, 10b5-1 Trading Plan, Director, Insider Trading